

IFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/812,448  
Applicant: Stuyver  
Filed: March 29, 2004  
TC/A.AU.: 1614  
Examiner: Unassigned

Confirmation No.: 3346

Docket No.: 08841.105059 PHA 2070 US  
Customer No.: 20786  
Title: Compounds For the Treatment of Flaviviridae Infections

Mail Stop Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450


INFORMATION DISCLOSURE STATEMENT

Sir:

The citation of information on the accompanying Form PTO/SB/08A, "Information Disclosure Statement by Applicant" is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each reference is enclosed. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Applicant does not believe any fees are due because this paper is submitted before the mailing of a first Office action on the merits, as under 37 C.F.R. § 1.97(b)(3). However, the Commissioner is hereby authorized to charge any fees due or credit any overpayment, to Deposit Account No. 11-0980.

Respectfully submitted,

  
Madeline Johnston, Ph.D., Esq.  
Reg. No. 36,174

Dated: November 5, 2004  
King & Spalding LLP  
191 Peachtree Street  
45<sup>th</sup> Floor  
Atlanta, GA 30303-1763  
Office: (404)572-4600/ Fax: 404-572-5145



## INFORMATION DISCLOSURE STATEMENT

### Certificate of Mailing Under 37 CFR 1.10

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the below-identified date.

Deposit Date: November 5, 2004

Docket No.: 08841.105059 PHA 2070 US

A handwritten signature in cursive script that reads "Minikia Blair". The signature is written over a horizontal line.

Minikia D. Blair  
Paralegal



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

6

**Complete if Known**

Application Number	10/812,448
Filing Date	March 29, 2004
First Named Inventor	Stuyver
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	08841.105059 PHA 2070 US

3598997\_1.DOC

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages / Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	AA	3,798,209	A	Witkowski <i>et al.</i>	03-19-1974	
	AB	Re. 29,835	Re.	Witkowski <i>et al.</i>	11-14-1978	
	AC	4,211,771	A	Witkowski <i>et al.</i>	07-08-1980	
	AD	5,767,097	A	Tam	06-16-1998	
	AE	5,830,455	A	Valtuna <i>et al.</i>	11-03-1998	
	AF	6,063,628	A	Loeb <i>et al.</i>	05-16-2000	
	AG	6,063,772	A	Tam	05-26-2000	
	AH	6,150,337	A	Tam	11-21-2000	
	AI	6,348,587	B1	Schinazi <i>et al.</i>	02-19-2002	
	AJ	6,423,695	B1	Tam <i>et al.</i>	07-23-2002	
	AK	6,455,508	B1	Ramasamy <i>et al.</i>	09-24-2002	
	AL	6,455,690	B1	Tam <i>et al.</i>	09-24-2002	
	AM	6,479,463	B1	Wang <i>et al.</i>	11-12-2002	
	AN	6,495,677	B1	Ramasamy <i>et al.</i>	12-17-2002	
	AO	6,509,320	B1	Wang <i>et al.</i>	01-21-2003	
	AP	6,573,248	B2	Ramasamy <i>et al.</i>	06-03-2003	
	AQ	6,660,721	B1	Devos <i>et al.</i>	12-09-2003	
	AR	6,777,395	B1	Bhat <i>et al.</i>	08-17-2004	
	AS	6,784,161	B1	Ismaili <i>et al.</i>	08-31-2004	
	AT	6,784,166	B1	Devos <i>et al.</i>	08-31-2004	
	AU	2002/0019363	A1	Ismaili <i>et al.</i>	02-14-2002	
	AV	2002/0055483	A1	Watanabe <i>et al.</i>	05-09-2002	
	AW	2002/0058635	A1	Averett	05-16-2002	
	AX	2002/0137696	A1	Tam	09-26-2002	
	AY	2002/0147160	A1	Bhat <i>et al.</i>	10-10-2002	
	AZ	2002/0147160	A1	Bhat <i>et al.</i>	10-10-2002	
	AZ	2002/0156030	A1	Ramasamy <i>et al.</i>	10-24-2002	
	AAA	2002/0198171	A1	Schinazi <i>et al.</i>	12-26-2002	
	AAB	2003/0008841	A1	Devos <i>et al.</i>	01-09-2003	
	AAC	2003/0028013	A1	Wang <i>et al.</i>	02-06-2003	
	AAD	2003/0050229	A1	Sommadosi <i>et al.</i>	03-13-2003	
	AAE	2003/0060400	A1	LaColla <i>et al.</i>	03-27-2003	
	AAF	2003/0083307	A1	Devos <i>et al.</i>	05-01-2003	
	AAG	2003/0087873	A1	Stuyver <i>et al.</i>	05-08-2003	

Examiner  
SignatureDate Con-  
sidered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Complete if Known</b>	
				Application Number	10/812,448
				Filing Date	March 29, 2004
				First Named Inventor	Stuyver
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	2	of	6	Attorney Docket Number	08841.105059 PHA 2070 US

3598997 1.DOC

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages / Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	BA	2003/0119764	A1	Loeb <i>et al.</i>	06-26-2003	
	BB	2003/0124512	A1	Stuyver	07-03-2003	
	BC	2003/0225029	A1	Stuyver	12-04-2003	
	BD	2003/0236216	A1	Devos <i>et al.</i>	12-25-2003	
	BE	2004/0002476	A1	Stuyver <i>et al.</i>	01-01-2004	
	BF	2004/0002596	A1	Hong <i>et al.</i>	01-01-2004	
	BG	2004/0006002	A1	Sommadossi <i>et al.</i>	01-08-2004	
	BH	2004/0006007	A1	Gosselin <i>et al.</i>	01-08-2004	
	BI	2004/0063622	A1	Sommadossi <i>et al.</i>	04-01-2004	
	BJ	2004/0067877	A1	Schinazi <i>et al.</i>	04-08-2004	
	BK	2004/0067901	A1	Bhat <i>et al.</i>	04-08-2004	
	BL	2004/0072788	A1	Bhat <i>et al.</i>	04-15-2004	
	BM	2004/0077587	A1	Sommadossi <i>et al.</i>	04-22-2004	
	BN	2004/0082574	A1	Wang <i>et al.</i>	04-29-2004	
	BO	2004/0097461	A1	Sommadossi <i>et al.</i>	05-20-2004	
	BP	2004/0097462	A1	Sommadossi <i>et al.</i>	05-20-2004	
	BQ	2004/0101535	A1	Sommadossi <i>et al.</i>	05-27-2004	
	BR	2004/0102414	A1	Sommadossi <i>et al.</i>	05-27-2004	
	BS	2004/0110717	A1	Carroll <i>et al.</i>	06-10-2004	
	BT	2004/0110718	A1	Devos <i>et al.</i>	06-20-2004	

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number	Kind Code <sup>2</sup> (if known)				
	BU	JP	61-130299 ✓	A	Daiken Koyo KK	06-18-1986		
	BV	WO	02/03997 ✓	A1	ICN Pharmaceuticals, Inc.	01-17-2001		
	BW	WO	02/048165 ✓	A2	Pharmasset Limited	06-20-2002		
	BX	WO	03/051899 ✓	A1	Ribapharm	06-26-2003		
	BY	WO	03/061385 ✓	A1	Ribapharm	07-31-2003		
	BZ	WO	03/061576 ✓	A2	Ribapharm	07-31-2003		
	BAA	WO	03/062255 ✓	A2	Ribapharm	07-31-2003		

Examiner Signature		Date Con- sidered	
-----------------------	--	----------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Complete if Known</b>	
				Application Number	10/812,448
				Filing Date	March 29, 2004
				First Named Inventor	Stuyver
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	3	of	6	Attorney Docket Number	08841.105059 PHA 2070 US

3598997 1.DOC

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number	Kind Code <sup>2</sup> (if known)				
	CA	WO	03/062256	A1	Ribapharm	07-31-2003		
	CB	WO	03/062257	A1	Ribapharm	07-31-2003		
	CC	WO	2004/003138	A1	Merck & Co.; Isis Pharmaceuticals	01-08-2004		
	CD	WO	2004/007512	A2	Merck & Co.; Isis Pharmaceuticals	01-22-2004		
	CE	WO	2004/009020	A2	Merck & Co.; Isis Pharmaceuticals	01-29-2004		
	CF	WO	2004/084796	A2	Pharmasset Limited	10-07-2004		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	CG	AGBARIA, R., <i>et al.</i> , "Antiproliferative effects of cyclopentenyl cytosine (NSC 375575) in human glioblastoma cells," <i>Oncol Res.</i> , 9:111-118 (1997).	
	CH	ALI, S.M., <i>et al.</i> , "Efficient enantioselective syntheses of carbocyclic nucleoside and prostaglandin synthons," <i>Tetrahedron Letters</i> , 31(11):1509-1512 (1990).	
	CI	BALZARINI, J., <i>et al.</i> , "Effect of antimetabolite drugs of nucleotide metabolism on the anti- human immunodeficiency virus activity of nucleoside reverse transcriptase inhibitors," <i>Pharmacol. Ther.</i> 87:175-187 (2000).	
	CJ	BATTAGLIA, A.M., <i>et al.</i> , "Combination therapy with interferon and ribavirin in the treatment of chronic hepatitis C infection," <i>Ann. Pharmacother.</i> 34(4):487-494 (April 2000).	
	CK	BERENGUER, M., <i>et al.</i> "Hepatitis C virus in the transplant setting," <i>Antivir. Ther.</i> 3(Suppl. 3):125-136 (1998).	
	CL	BIANCHI, V., <i>et al.</i> , "Inhibition of ribonucleotide reductase by 2'-substituted deoxycytidine analogs: possible application in AIDS treatment," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 91:8403-8407 (1994).	
	CM	BUDAVARI, S., Editor, The Merck Index, 11th edition, Merck & Co., Inc., Rahway, NJ, p1304, 1989 [Ribavirin (1-β-D-ribofuranosyl-1-1,2,4-triazole-3-carboxamide) / Virazole <sup>TM</sup> ].	
	CN	CARROLL, S.S., <i>et al.</i> , "Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs," <i>J. Biol. Chem.</i> , 278(14):11979-11984 (April 4, 2003).	
	CO	CHU, C.K., <i>et al.</i> , "Nucleosides. 117. synthesis of 4-oxo-B-(β-D-ribofuranosyl)-3H-pyrazolo[1,5a]-1,3,5-triazine (OPTR) via 3-amino-2N-carbamoyl-4-(β-D-ribofuranosyl)pyrazole (ACPR) derivatives," <i>J. Heterocycl. Chem.</i> , 17:1435-1439 (1980).	
	CP	CRANCE, J.M., <i>et al.</i> , "Inhibition of sandfly fever Sicilian virus (Phlebovirus) replication in vitro by antiviral compounds," <i>Res. Virol.</i> , 148:353-365 (1997).	

Examiner Signature		Date Con- sidered	
-----------------------	--	----------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Complete if Known</b>	
				Application Number	10/812,448
				Filing Date	March 29, 2004
				First Named Inventor	Stuyver
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	4	of	6	Attorney Docket Number	08841.105059 PHA 2070 US

3598997 1.DOC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	DA	DAVIS, G.L., "Current therapy for chronic hepatitis C," <i>Gastroenterology</i> , 118(2 Suppl. 1):S104-S114 (2000).	
	DB	De CLERCQ, E., <i>et al.</i> "Broad-spectrum antiviral and cytotoxic activity of cyclopentenylcytosine, a carbocyclic nucleoside targeted at CTP synthetase," <i>Biochem. Pharmacol.</i> , 41(12):1821-1829 (1991).	
	DC	DOLLINGER, M.R., <i>et al.</i> , "Analogues of 1-β-D-arabinofuranosylcytosine. Studies of mechanisms of action in Burkitt's cell culture and mouse leukemia, and in vitro deamination studies," <i>Biochemical Pharmacology</i> , 16(4):689-706 (April 1967).	
	DD	DUSCHINSKY, R., <i>et al.</i> , "Nucleosides. XXXVII. 5,6-substituted 5-fluorodihydropyrimidines and their 2'-deoxyribonucleosides," <i>J. Med. Chem.</i> , 10(1):47-58 (January 1967).	
	DE	HEINEMANN, V., <i>et al.</i> , "Gemcitabine: A modulator of intracellular nucleotide and deoxynucleotide metabolism," <i>Semin. Oncol.</i> , 22:11-18 (1995).	
	DF	HOSHINO, J., <i>et al.</i> , "Suppression of nuclear ADP-ribosyltransferase activity in Ehrlich ascites tumor cells by 5-azacytidine and its analogs," <i>Biochemical and Biophysical Research Communications</i> , 142(2):468-474 (January 30 1987).	
	DG	IKEHARA, M., <i>et al.</i> , "Studies of nucleosides and nucleotides. XXXII. Purine cyclonucleosides. 3. Synthesis of 2'-deoxy- and 3'-deoxyadenosine from adenosine," <i>Chem. Pharm. Bull.</i> , 15(1):94-100 (January 1967).	
	DH	KABAT, M.M., <i>et al.</i> , "Synthesis of 5-beta-D-ribofuranosylnicotinamide and its N-methyl derivative. The isosteric and isoelectronic analogues of nicotinamide nucleoside," <i>J. Med. Chem.</i> , 30(5):924-927 (May 1987).	
	DI	KANEKO, M., <i>et al.</i> , "Synthesis and properties of 8,2'-cyclothioguanosine and related compounds," <i>Chem. Pharm. Bull.</i> , 20(3):635-637 (1972).	
	DJ	KAZIMIERCZUK, Z., <i>et al.</i> , "Synthesis of 2'-deoxytubercidin, 2'-deoxyadenosine, and related 2'-deoxynucleosides via a novel direct stereospecific sodium salt glycosylation procedure," <i>J. Am. Chem. Soc.</i> , 106(21):6379-6382 (1984).	
	DK	LEE, W. W., <i>et al.</i> , "Potential anticancer agents. LV. Synthesis of 3'-amino-2',3'-dideoxyadenosine and related analogs," <i>J. Am. Chem. Soc.</i> , 83:1906-1911 (April 20, 1961).	
	DL	LIN, T. S., <i>et al.</i> , "Synthesis and anticancer activity of various 3'-deoxy pyrimidine nucleoside analogs, and crystal structure of 1-(3-deoxy-β-D-threo-pentofuranosyl)cytosine," <i>J. Med. Chem.</i> , 34(2):693-701 (1991).	
	DM	LOCKSHIN, A., <i>et al.</i> , "Selective cytotoxicity of 5-hydroxyuridine for human colon adenocarcinoma cells," <i>Cancer Treatment Reports</i> , 69(7-8):845-850 (July-August 1985).	
	DN	LOHMANN, V., <i>et al.</i> , "Biochemical and kinetic analyses of NS5B RNA-dependent RNA polymerase of the hepatitis C virus," <i>Virology</i> , 249(1):108-118 (September 15, 1998).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Complete if Known</b>	
				Application Number	10/812,448
				Filing Date	March 29, 2004
				First Named Inventor	Stuyver
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	5	of	6	Attorney Docket Number	08841.105059 PHA 2070 US

3598997 1.DOC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	EA	MARKLAND, W., <i>et al.</i> , "Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: A comparison with ribavirin and demonstration of antiviral additivity with alpha interferon," <i>Antimicrob. Agents Chemother.</i> , 44(4):859-866 (April 2000).	
	EB	MARUMOTO, R., <i>et al.</i> , "One-step halogenation at the 2'-position of uridine, and related reactions of cytidine and N <sup>4</sup> -acetylcytidine," <i>Chem. Pharm. Bull.</i> , 22(1):128-134 (1974).	
	EC	MENDEZ, E., <i>et al.</i> , "Infectious bovine viral diarrhea virus (strain NADL) RNA from stable cDNA clones: a cellular insert determines NS3 production and viral cytopathogenicity," <i>J. Virol.</i> , 72(6):4737-4745 (1998).	
	ED	MORREY, J.D., <i>et al.</i> , "Identification of active antiviral compounds against a New York isolate of West Nile virus," <i>Antiviral Res.</i> , 55:107-116 (2002).	
	EE	NEYTS, J., <i>et al.</i> , "Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections," <i>Antiviral Res.</i> , 30:125-132 (1996).	
	EF	NIEDEBALLA, U., <i>et al.</i> , "A general synthesis of N-glycosides. 6. On the mechanism of the stannic chloride catalyzed silyl Hilbert-Johnson reaction," <i>J. Org. Chem.</i> , 41(12):2084-2086 (June 11, 1976).	
	EG	OZOLS, A. M., <i>et al.</i> , "Aminonucleosides and the derivatives. VI. A new synthesis of 1,2,5-tri-I-O-3-azido-3-deoxy-β-D-ribofuranose," <i>Synthesis</i> , 1980:557-559 (1980).	
	EH	PANKIEWICZ, K. W., <i>et al.</i> , "A synthesis of ψ-cytidine," <i>Carbohydr. Res.</i> , 127(2):227-233 (April 15, 1984).	
	EI	PANKIEWICZ, K. W., <i>et al.</i> , "Synthesis of 2,2'-anhydro-2-hydroxy- and 6,2'-anhydro-6-hydroxy-1-β-D-arabinofuranosylnicotinamide as conformationally restricted nicotinamide nucleoside analogs," <i>Nucleosides &amp; Nucleotides</i> , 10:1333-1344 (1991).	
	EJ	PLUNKETT, W., <i>et al.</i> , "Gemcitabine: metabolism, mechanisms of action, and self-potential," <i>Semin. Oncol.</i> , 22:3-10 (1995).	
	EK	POLITI, P.M., <i>et al.</i> , "Phase I clinical trial of continuous infusion cyclopentenyl cytosine," <i>Cancer Chemother. Pharmacol.</i> , 36:513-523 (1995).	
	EL	ROBERTS, M., <i>et al.</i> , "Uridine and cytidine derivatives," <i>J. Am. Chem. Soc.</i> , 74:668-669 (February 5, 1952).	
	EM	SERGUEEVA, Z. A., <i>et al.</i> , "Rapid and selective reduction of amide group by borane-amine complexes in acyl protected nucleosides," <i>Nucleosides Nucleotides Nucleic Acids</i> , 19(1-2):275-282 (January-February 2000).	
	EN	SHI, J., <i>et al.</i> , "Synthesis and biological evaluation of 2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine (D4FC) analogues: Discovery of carbocyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase," <i>J. Med. Chem.</i> , 42(5):859-867 (1999).	
	EO	STAVBER, S., <i>et al.</i> , "Room-temperature reactions of CsSO <sub>4</sub> F with organic molecules containing heteroatoms," <i>J. Chem. Soc. Chem. Commun.</i> , 1983:563-564 (1983).	
Examiner Signature			Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Complete if Known</b>	
				Application Number	10/812,448
				Filing Date	March 29, 2004
				First Named Inventor	Stuyver
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	6	of	6	Attorney Docket Number	08841.105059 PHA 2070 US

3598997 1.DOC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	FA	STUYVER, L.J. <i>et al.</i> , "Inhibitors of the IMPDH enzyme as potential anti-bovine viral diarrhea virus agents," <i>Antiviral Chem. Chemother.</i> , 13:345-352 (2003).	
	FB	STUYVER, L.J., <i>et al.</i> , "Ribonucleoside analogue that blocks the replication of bovine viral diarrhea and hepatitis C viruses in culture," <i>Antimicrob. Agents Chemother.</i> , 47(1):244-254 (January 2003).	
	FC	SUHADOLNIK, R. J., <i>et al.</i> , "Synthesis of 3'-deoxyuridine via transglycosylation of uracil with 3'-deoxyadenosine (cordycepin)," <i>Carbohydr. Res.</i> , 61:545-548 (1978).	
	FD	SUTTLE, D.P., <i>et al.</i> , "Coordinate overproduction of orotate phosphoribosyltransferase and orotidine-5'-phosphate decarboxylase in hamster cells resistant to pyrazofurin and 6-azauridine," <i>J. Biol. Chem.</i> , 254:4602-4607 (1979).	
	FE	TANAKA, H., <i>et al.</i> , "A simplified synthesis of 8-substituted purine nucleosides via lithiation of 6-chloro-9-(2,3-O-isopropylidene-β-D-ribofuranosyl) purine," <i>Chem. Pharm. Bull.</i> , 31(2):787-790 (1983).	
	FF	TANAKA, H., <i>et al.</i> , "Regiospecific C-alkylation of uridine: A simple route to 6-alkyluridines," <i>Tetrahedron Lett.</i> , 1979(49):4755-4758 (1979).	
	FG	THURBER, T. C., <i>et al.</i> , "A novel ring contraction of O <sup>5</sup> -6(S)-cyclo-5-diazouridine. Elimination of a ring carbonyl group in preference to diatomic nitrogen," <i>J. Am. Chem. Soc.</i> , 95(9):3081-3082 (May 2, 1973).	
	FH	WACHSMAN, M., <i>et al.</i> , "Anticytomegaloviral activity of methotrexate associated with preferential accumulation of drug by cytomegalovirus-infected cells," <i>Antimicrob. Agents Chemother.</i> , 40(2):433-436 (February 1996).	
	FI	WALKER, M.P., <i>et al.</i> , "HCV RNA-dependent RNA polymerase as a target for antiviral development," <i>Curr. Opin. Pharmacol.</i> , 2:1-7 (2002).	
	FJ	WALTON, E., <i>et al.</i> , "3'-Deoxynucleosides. I. A synthesis of 3'-deoxyadenosine," <i>J. Am. Chem. Soc.</i> , 86:2952 (1964).	
	FK	WATANABE, "The Chemistry of C-Nucleosides", in TOWNSEND, L. B., Ed., In "Chemistry of Nucleosides and Nucleotides", Plenum Publ., New York, Vol., 3, page 421-465 (1994).	
	FL	WOLFE, M.S., <i>et al.</i> , "Enantiospecific syntheses of aristeromycin and neplanocin A," <i>J. Org. Chem.</i> , 55:4712-4717 (1990).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.